Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

CRISPR Therapeutics AG (CRSP) Down 16.5% Since Last Earnings Report: Can It Rebound?

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

CRISPR Therapeutics' (CRSP) Pipeline Development Fuels Growth

Markforged Holding Corp

UiPath

Regeneron Pharmaceuticals

Stratasys

Tesla

Unity Software

Cathie Wood is well-known in the investment world as the face of ARK Invest, the firm she founded in 2014. ARK itself stands for Active Research Knowledge.

7 Cathie Wood Stocks to Buy on the Dip

DraftKings

Zoom Video

Beam Therapeutics

Ginkgo Bioworks Holdings

This article is excerpted from Tom Yeung's Profit & Protection newsletter dated Aug. 16, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.

5 Cathie Wood Stocks Signaling “The Bear Market Is Over”

ARK Genomic Revolution Multi-Sector ETF

Editas Medicine

Global X Genomics & Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

A Comprehensive Guide to Genomic ETFs

Americold Realty

MacroGenics

Take-Two Interactive Software

Markets were on the rise Wednesday after a relatively positive consumer price index (CPI) report.

Barclays Picks 2 Winners and 2 Losers After Earnings

CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.

CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates

Crispr Therapeutics is perhaps the most speculative name I'm currently buying, though in small sizes, with an expectation to "don't look, don't sell" for at least 10 years. Analysts expect this company to lose money for the next three years, but with a chance of earning 25-50% of its current stock price every year from 2029-2031.

Crispr: My Long-Term 'Wait And Watch' Punt On The Future Of Gene Editing

-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA); discussions with the U.S. Food and Drug Administration (FDA) ongoing-

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Alnylam Pharmaceuticals

Intellia Therapeutics

Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted the entire industry.

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?

The next 12 months could look very different from the past year for this biotech company.

Where Will CRISPR Therapeutics Be in 1 Year?

This article reviews the current state of affairs for CRISPR Therapeutics so you can decide if the gene editing company is worth a speculative investment

Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?

Crispr Therapeutics continues to make progress toward submitting a global regulatory filing for CTX001. CTX130 preliminary data shows the power of Crispr Cas-9 technology.

Crispr Therapeutics' Continued Progress Warrants A Buy

Exelixis

These companies' shares have outpaced the market and other biotech stocks this year.

2 Biotech Stocks to Help Recession-Proof Your Portfolio

Exact Sciences

First Commonwealth Financial

Roku

As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers. The post 6 Cathie Wood Stocks to Buy on the Dip appeared first on InvestorPlace.

6 Cathie Wood Stocks to Buy on the Dip

Cerus

Signify Health

The Best 3 Stocks in Cathie Wood's Ark ETF Have 1 Thing in Common

Biogen

Vertex Pharmaceuticals

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on InvestorPlace.

7 Moonshot Investments Upending a $10 Trillion Industry

bluebird bio

These high-tech biotech stocks made a sharp U-turn this week after a rough start to the year.

Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week

Amgen

iShares Nasdaq Biotechnology ETF

Ionis Pharma

Merck

Twist Bioscience Corp

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. The post 7 Best Biotech Stocks to Buy in July 2022 appeared first on InvestorPlace.

7 Best Biotech Stocks to Buy in July 2022

This is a dedicated price action analysis of CRISPR stock. We highlight why investors should consider cutting exposure as CRSP formed another bull trap in June, corroborating its bearish bias. Investors should note that we have not observed any significant bear traps that can help sustain its bottom. Therefore, we expect a potentially steeper fall ahead.

Crispr Therapeutics: Use The Rally To Cut

On the long way down, in what appears to be a clear-cut recession, investors are looking at picking up names on the cheap for when the turnaround kicks in.

Will CRISPR Stock Double in the Next Year?

Crispr Therapeutics Chief Executive Sam Kulkarni says the next two years of clinical trials and data readouts will give investors, and patients, plenty to cheer about.

Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

CRISPR Therapeutics shares traded as high as $200 18 months ago, but today the share price is $62, with a market cap valuation $4.75bn. I see that as a BUY opportunity. On Tuesday the company held an "Innovation Day" to showcase its entire pipeline.

Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long Term

Seagen

SPDR S&P Biotech ETF

It's probably better to think about whether to buy more shares.

Should You Sell Biotech Stocks If There's a Recession?

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading lower Wednesday after several analysts adjusted price targets on the stock following the company's Innovation Day. CRISPR Therapeutics stock plunged Tuesday during its Innovation Day after the company signaled that it.

Why CRISPR Therapeutics Stock Is Falling

News for CRISPR Therapeutics Stock (CRSP)